Discover the Copay Assistance Program

Eligible commercially insured patients may qualify for the Doptelet Copay Assistance Program

What's the program?

Eligible patients may pay as little as $0 for each Doptelet prescription
Annual maximum benefit up to $15,000

Eligible patients must:

Have commercial insurance that covers Doptelet
Not be enrolled in any state or covered by a state or federal healthcare program such as Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD), or TRICARE
Be 18 years of age or older
Be a resident in the United States or a US Territory
Be prescribed Doptelet for an FDA-approved use

How to enroll:

Approved pharmacies, healthcare professionals, and Doptelet Connect can enroll patients
Patients can enroll themselves as well as their caregivers
Please call 1-833-368-2663 Monday–Friday 8 am–8 pm ET for more information

Terms and Conditions

Patients pay as little as $0 per prescription. Copay Assistance Program has an annual calendar cap of $15,000
Patient has an on-label prescription
The Copay Assistance Program is void where prohibited by law, taxes, or restricted
This offer is non-transferable, no substitutions are permissible, and this offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
Sobi, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice
The Copay Assistance Program for Doptelet is not insurance and is not intended to substitute for insurance
Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Copay Assistance Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Copay Assistance Program
Certain information pertaining to your use of the Copay Assistance Program will be shared with Sobi, Inc., the sponsor of the Copay Assistance Program. The information disclosed will include the date the prescription is filled, the number of pills or product dispensed by the pharmacists, and the amount of your copay that will be paid for by using this Copay Assistance Program. For more information, please see the Sobi Privacy Policy at https://sobi-northamerica.com/privacy-policy
Acceptance in this Copay Assistance Program is not conditioned on any past, present, or future purchase, including additional doses
Enrollment for the Copay Assistance Program is valid through the calendar year
Sobi reserves the right to change Copay Assistance Program terms at any time

For US healthcare professionals only
Important Safety Information
Prescribing Information
Patient Information Leaflet
For Patients

DOPTELET DOSING TO TARGET THE RIGHT RESPONSE

Help your patients reach their chronic ITP treatment goals.

Titrate on your terms¹

The recommended starting dose is 20 mg once daily with food and dose adjust as needed.

Disclaimer: The minimum dose on Doptelet is 20 mg once weekly and the maximum is 40 mg once daily.

Dose adjustments may be needed based on platelet response and for patients taking moderate or strong dual inducers or inhibitors of CYP2C9 and CYP3A4.*

Start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 20 mg 3 times a week; start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 40 mg once daily.^1,2 Please see Full Prescribing Information for additional information on dose adjustments.

After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of ≥50×10⁹/L has been achieved, and then obtain platelet counts monthly thereafter.

Titration Calculator¹

Want more information on dosing & titration?
Answer these 3 questions:

I’m looking for dosing recommendations for:

Starting patients on DopteletTitrating for a patient
already taking Doptelet

Taken on their terms^1,3,4

Doptelet is the only oral TPO-RA of its kind that your patients can take based on their schedule.¹

Patients are required to take Doptelet with food and on a consistent schedule
Patients can take Doptelet at home

Doptelet Platelet Character Shooting Broccoli Out of Cannon

Set treatment goals from the start

One goal of chronic ITP treatment is to increase and maintain a stable platelet count
Additional factors to consider when discussing treatment goals with your patients include the duration of ITP, frequency of bleeding episodes, increased risk factors for thromboembolism, comorbidities, age, medication adherence, support networks, patient preference, cost, and availability

Let’s Dig In

Doptelet Dosing

Visit the video library to view more.

View Video

References:

1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
2. Data on file. Extend of exposure. 2022: Sobi, Inc.
3. Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021.
4. Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen; 2022.

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

DOPTELET^® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

Adverse Reactions

The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

For WAC pricing, visit doptelethcp.com/wac-pricing.

INDICATION & IMPORTANT
SAFETY INFORMATION